1. Scrip

A Plea For Patience: Bristol/Nektar's Opdivo/NKTR-214 Combo Responses Deepen Over Time

 
• By Emily Hayes

The cancer immunotherapy combo showed "remarkable" effects in patients who tested negative for PD-L1 expression and would normally not respond well to immunotherapy. 

T-cells attacking cancer_1200x675

The combination of Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo with Nektar Therapeutics's IL-2 agent NKTR-214 yielded deepening responses over time and demonstrated signs of being able to turn immunologically "cold" tumors "hot" – making them susceptible to immuno-oncology approaches, specialists reported at the American Society of Clinical Oncology (ASCO) annual meeting June 2.

Bristol and Nektar have been partnered since February on NKTR-214's development in nine tumor types and 20 indications, under a massive development deal signed in February worth $1.85bn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.